4//SEC Filing
ACADIA PHARMACEUTICALS INC 4
Accession 0001415889-13-001869
$ACADCIK 0001070494operating
Filed
Sep 19, 8:00 PM ET
Accepted
Sep 20, 6:52 PM ET
Size
9.2 KB
Accession
0001415889-13-001869
Insider Transaction Report
Form 4
Mills Roger
Executive VP, Development
Transactions
- Sale
Common Stock
2013-09-20$25.01/sh−35,965$899,312→ 15,775 total - Exercise/Conversion
Common Stock
2013-09-20+35,965→ 51,740 total - Exercise/Conversion
Stock Option (right to buy)
2013-09-20−35,965→ 164,035 totalExercise: $1.55Exp: 2020-03-11→ Common Stock (35,965 underlying)
Footnotes (4)
- [F1]Includes 1,758 shares acquired on May 31, 2013 by Dr. Mills under the ACADIA Pharmaceuticals Employee Stock Purchase Plan.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2013.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.05 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- [F4]25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
Documents
Issuer
ACADIA PHARMACEUTICALS INC
CIK 0001070494
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001070494
Filing Metadata
- Form type
- 4
- Filed
- Sep 19, 8:00 PM ET
- Accepted
- Sep 20, 6:52 PM ET
- Size
- 9.2 KB